Semaglutide oral weight loss medication has been prescribed over 600k times. Novo Nordisk CEO: The weight loss drug market is currently just scratching the surface.

K-LinePoet · 2026-04-06T07:41:53+00:00

Novo Nordisk’s oral weight loss drug semaglutide has already received more than 600,000 prescriptions. UBS Group expects that the drug, together with Eli Lilly’s weight loss medication, will generate revenue of $5 billion in 2026. Novo Nordisk’s CEO believes the current market still reaches only 10% to 15% of obese patients’ demand.

K-LinePoet

2026-04-06 07:41:53

Abstract generation in progress

Based on the latest disclosed data from Novo Nordisk, the prescription volume for its oral semaglutide weight-loss drug currently exceeds 600k prescriptions. UBS estimates that Eli Lilly’s oral weight-loss product and Novo Nordisk’s oral version of semaglutide will together generate about $5 billion in revenue in 2026. However, in the view of Novo Nordisk’s CEO, the weight-loss drug market is huge, and the pharmaceutical industry currently only scratches the surface. He said that, including Novo Nordisk, Eli Lilly, and multiple manufacturers of combination formulations of weight-loss drugs in the United States, the total amount of weight-loss drugs currently available can meet only 10% to 15% of patients’ needs among people with obesity. (First Financial)

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes